quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·101d
NEWSRelease
CASI Pharmaceuticals Inc. logo

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

CASI· CASI Pharmaceuticals Inc.
Health Care
Original source

Companies

  • CASI
    CASI Pharmaceuticals Inc.
    Health Care

Related

  • SEC56d
    SEC Form D filed by CASI Pharmaceuticals Inc.
  • SEC57d
    SEC Form 6-K filed by CASI Pharmaceuticals Inc.
  • NEWS57d
    CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
  • SEC62d
    SEC Form 6-K filed by CASI Pharmaceuticals Inc.
  • SEC63d
    SEC Form 6-K filed by CASI Pharmaceuticals Inc.
  • SEC65d
    Amendment: SEC Form SCHEDULE 13G/A filed by CASI Pharmaceuticals Inc.
  • SEC69d
    Amendment: SEC Form SCHEDULE 13G/A filed by CASI Pharmaceuticals Inc.
  • SEC72d
    SEC Form 6-K filed by CASI Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022